The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | A Phase II study of the LSD1 inhibitor bomedemstat in patients with polycythemia vera
Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, discusses an ongoing study investigating bomedemstat, an inhibitor of lysine-specific demethylase 1 (LSD1), in the treatment of polycythemia vera (PV). This agent has shown efficacy in myelofibrosis (MF) and essential thrombocythemia (ET), with the potential to be disease-modifying rather than just treating symptoms. Outcomes in patients with PV are awaited. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
